#Multiple_Myeloma hashtag - Bluesky

@newsen.bsky.social

2 weeks ago

IASO Bio Secures PMDA Approval for CAR-T Therapy Trial Against Multiple Myeloma IASO Bio has gained official clearance from Japan's PMDA for clinical trials of Equecabtagene Autoleucel, targeting multiple myeloma patients. This marks a significant step in cancer treatment innovation.

IASO Bio Secures PMDA Approval for CAR-T Therapy Trial Against Multiple Myeloma #Japan #Tokyo #CAR-T_therapy #Multiple_Myeloma #IASO_Bio

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

Johnson & Johnson's FDA Approval of TECVAYLI® and DARZALEX FASPRO® Provides New Hope for Multiple Myeloma Treatment The FDA has approved TECVAYLI® and DARZALEX FASPRO® for relapsed/refractory multiple myeloma, marking a significant advancement in treatment options. This combination therapy may change treatment standards for patients.

Johnson & Johnson's FDA Approval of TECVAYLI® and DARZALEX FASPRO® Provides New Hope for Multiple Myeloma Treatment #United_States #Multiple_Myeloma #Horsham #DARZALEX_FASPRO #TECVAYLI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

XPOVIO® Gains Reimbursement Approval in South Korea for Multiple Myeloma Treatment Expansion Antengene Corporation's XPOVIO® has received approval for reimbursement in South Korea for multiple myeloma, benefiting more patients in the region.

XPOVIO® Gains Reimbursement Approval in South Korea for Multiple Myeloma Treatment Expansion #South_Korea #Seoul #XPOVIO #Multiple_Myeloma #Antengene

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Johnson & Johnson Gains FDA Success With DARZALEX FASPRO® in Myeloma Treatment Johnson & Johnson announces the FDA's approval of DARZALEX FASPRO® for newly diagnosed multiple myeloma patients who cannot undergo transplant, marking a significant advancement in cancer treatment.

Johnson & Johnson Gains FDA Success With DARZALEX FASPRO® in Myeloma Treatment #United_States #Johnson_&_Johnson #Multiple_Myeloma #DARZALEX_FASPRO #HORSHAM,_Pennsylvania

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Innovent's IBI3003 Antibody Gains Fast Track Status for Multiple Myeloma Treatment The FDA has granted Innovent's IBI3003 Fast Track Designation for treating relapsed multiple myeloma, enhancing development and approval speeds.

Innovent's IBI3003 Antibody Gains Fast Track Status for Multiple Myeloma Treatment #United_States #San_Francisco #Multiple_Myeloma #Innovent #IBI3003

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Exciting Advances in Multiple Myeloma Treatments Revealed at ASH 2025 Conference The ASH 2025 Annual Meeting showcased groundbreaking data on multiple myeloma treatments, highlighting potential functional cures and revolutionizing patient care.

Exciting Advances in Multiple Myeloma Treatments Revealed at ASH 2025 Conference #United_States #Orlando #Clinical_Trials #Multiple_Myeloma #ASH_2025

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

New Phase 3 MajesTEC-3 Study Data Highlights TECVAYLI® and DARZALEX FASPRO® as Potential New Standard for Relapsed Multiple Myeloma The Phase 3 MajesTEC-3 study reveals that TECVAYLI® combined with DARZALEX FASPRO® significantly improves outcomes for patients with relapsed multiple myeloma.

New Phase 3 MajesTEC-3 Study Data Highlights TECVAYLI® and DARZALEX FASPRO® as Potential New Standard for Relapsed Multiple Myeloma #United_States #Orlando #Multiple_Myeloma #TECVAYLI® #DARZALEX_FASPRO®

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Significant Progress in Treating Relapsed Refractory Multiple Myeloma with Tec-Dara Combination Therapy A recent trial has revealed that the Tec-Dara combination therapy significantly outperforms standard treatments in relapsed refractory multiple myeloma, offering new hope to patients.

Significant Progress in Treating Relapsed Refractory Multiple Myeloma with Tec-Dara Combination Therapy #USA #Orlando #Multiple_Myeloma #Daratumumab #Teclistamab

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

IASO Bio Shares Promising Updates for CAR-T Therapy in Multiple Myeloma at 2025 ASH IASO Bio introduced new clinical results for their CAR-T therapy, Equecabtagene Autoleucel (Eque-cel), for high-risk multiple myeloma patients at ASH 2025.

IASO Bio Shares Promising Updates for CAR-T Therapy in Multiple Myeloma at 2025 ASH #China #Shanghai #CAR-T_therapy #Multiple_Myeloma #IASO_Bio

2 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Leads Biolabs Unveils Promising Clinical Data for LBL-034 at 2025 ASH Annual Meeting At the 2025 ASH Annual Meeting, Leads Biolabs presented groundbreaking results on LBL-034, a bispecific antibody for relapsed myeloma patients, showcasing its effectiveness and safety.

Leads Biolabs Unveils Promising Clinical Data for LBL-034 at 2025 ASH Annual Meeting #USA #Leads_Biolabs #Orlando #Multiple_Myeloma #LBL-034

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent Biologics Reveals Promising Initial Results for IBI3003 in Treating Multiple Myeloma Innovent Biologics presents initial findings from its first-in-human trial of the trispecific antibody IBI3003 for relapsed multiple myeloma at ASH 2025.

Innovent Biologics Reveals Promising Initial Results for IBI3003 in Treating Multiple Myeloma #China #Suzhou #Multiple_Myeloma #Innovent #IBI3003

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

CARVYKTI® Shows Promise for Sustained Remissions in Multiple Myeloma Patients after 2.5 Years Recent results from Johnson & Johnson's CARTITUDE-4 study reveal that CARVYKTI® has led to significant treatment-free remissions in multiple myeloma patients for up to 2.5 years.

CARVYKTI® Shows Promise for Sustained Remissions in Multiple Myeloma Patients after 2.5 Years #USA #Johnson_&_Johnson #Orlando #Multiple_Myeloma #CARVYKTI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

K36 Therapeutics Releases Groundbreaking Clinical Data on Gintemetostat and Appoints New Chief Medical Officer K36 Therapeutics has unveiled promising first-in-human clinical data for Gintemetostat in multiple myeloma and announced Dr. Shinta Cheng as CMO.

K36 Therapeutics Releases Groundbreaking Clinical Data on Gintemetostat and Appoints New Chief Medical Officer #USA #Orlando #K36_Therapeutics #Multiple_Myeloma #Gintemetostat

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Darzalex Approval Marks Significant Milestone for High-Risk Smoldering Multiple Myeloma Treatment Darzalex has received regulatory approval for delaying progression in high-risk smoldering multiple myeloma, revolutionizing patient care.

Darzalex Approval Marks Significant Milestone for High-Risk Smoldering Multiple Myeloma Treatment #Japan #Johnson_&_Johnson #Tokyo #Multiple_Myeloma #DARZALEX

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

FDA Approves DARZALEX Faspro® for High-Risk Smoldering Multiple Myeloma Patients The FDA has approved DARZALEX Faspro® for adult patients with high-risk smoldering multiple myeloma, enabling earlier intervention and better outcomes.

FDA Approves DARZALEX Faspro® for High-Risk Smoldering Multiple Myeloma Patients #USA #San_Diego #Halozyme_Therapeutics #Multiple_Myeloma #DARZALEX_FASPRO

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Future of Multiple Myeloma Therapies: A Market Projection for 2033 The next-generation multiple myeloma therapies market is set to grow significantly, projected to reach USD 37.07 billion by 2033, driven by advances in treatments and technologies.

Future of Multiple Myeloma Therapies: A Market Projection for 2033 #USA #Austin #Immunotherapy #Multiple_Myeloma #DataM_Intelligence

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Innovative Dual Antibody Therapy for Difficult-to-Treat Multiple Myeloma Patients This article explores the recently submitted dual antibody therapy using Tarvey® and Tecvayli® for treating relapsed or refractory multiple myeloma with extramedullary disease.

Innovative Dual Antibody Therapy for Difficult-to-Treat Multiple Myeloma Patients #Japan #Tokyo #Multiple_Myeloma #TECVAYLI #Tarvey

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

New Data on Daratumumab-Based Therapy for Untreated Multiple Myeloma in Japan Recent findings reveal that the daratumumab-based four-drug therapy significantly improves treatment outcomes for untreated multiple myeloma patients in Japan, aligning with global data.

New Data on Daratumumab-Based Therapy for Untreated Multiple Myeloma in Japan #Japan #Tokyo #Multiple_Myeloma #Daratumumab

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Turby® Shows Sustained Efficacy in Japanese Patients with Recurrent Multiple Myeloma Turby® demonstrates deep and lasting responses in Japanese patients with recurrent or refractory multiple myeloma. A promising option for treatment.

Turby® Shows Sustained Efficacy in Japanese Patients with Recurrent Multiple Myeloma #Japan #Johnson_&_Johnson #Tokyo #Multiple_Myeloma #Turby®

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Teclistamab Shows Promising Effectiveness for Japanese Myeloma Patients in Long-Term Study A long-term follow-up study on teclistamab shows high response rates and prolonged effects in Japanese patients with refractory multiple myeloma.

Teclistamab Shows Promising Effectiveness for Japanese Myeloma Patients in Long-Term Study #Japan #Tokyo #Multiple_Myeloma #Teclistamab #Janssen_Pharmaceuticals

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Significant Improvements in Survival Rates Using TECVAYLI and DARZALEX FASPRO for Multiple Myeloma A recent Phase 3 study indicates that a combination of TECVAYLI and DARZALEX FASPRO enhances survival rates in multiple myeloma patients, showcasing groundbreaking therapeutic advancements.

Significant Improvements in Survival Rates Using TECVAYLI and DARZALEX FASPRO for Multiple Myeloma #USA #Multiple_Myeloma #DARZALEX_FASPRO #Raritan #TECVAYLI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Promising Results of TECVAYLI® and DARZALEX FASPRO® in Multiple Myeloma Treatment Revealed Recent data from Johnson & Johnson highlights the effectiveness of dual induction therapy using TECVAYLI® and DARZALEX FASPRO® for newly diagnosed multiple myeloma patients eligible for transplants.

Promising Results of TECVAYLI® and DARZALEX FASPRO® in Multiple Myeloma Treatment Revealed #USA #Toronto #Multiple_Myeloma #TECVAYLI® #DARZALEX_FASPRO®

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

K36 Therapeutics to Reveal Preclinical Insights for KTX-1001 at Myeloma Society Meeting K36 Therapeutics is set to present new preclinical findings on KTX-1001, aiming to improve treatment for multiple myeloma at the International Myeloma Society Meeting in Toronto.

K36 Therapeutics to Reveal Preclinical Insights for KTX-1001 at Myeloma Society Meeting #United_States #Cambridge #KTX-1001 #K36_Therapeutics #Multiple_Myeloma

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

CARsgen's Latest Findings on Zevor-cel at IMS 2025 Highlight Efficacy and Safety in Treating Multiple Myeloma The new long-term follow-up results for Zevor-cel, presented by CARsgen at IMS 2025, reveal promising efficacy and safety data for multiple myeloma patients.

CARsgen's Latest Findings on Zevor-cel at IMS 2025 Highlight Efficacy and Safety in Treating Multiple Myeloma #China #Shanghai #Multiple_Myeloma #CARsgen #Zevor-cel

2 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago